The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...
Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...
Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...
Nxera Pharma inks agreement with Holling Bio-Pharma to commercialize daridorexant in Taiwan: Tokyo, Japan Monday, March 3, 2025, 16:00 Hrs [IST] Nxera Pharma Co., Ltd. announces t ...
Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Filing of daridorexant in Taiwan planned ...
Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Filing of daridorexant in Taiwan ...